New (old) CureVac CEO on non-COVID-19 medical leave as plot thickens

CureVac is working on a COVID-19 vaccine using mRNA, but its leadership changes and political intrigue have become bigger talking points. (Getty Images)

CureVac’s embroilment in a crazy story just got a lot weirder: Two weeks back, it lost its CEO, who was without warning replaced by its old CEO. Now, he’s out for the foreseeable future with an undefined (but not COVID-19-related) medical issue suddenly stopping him from being chief.

This comes as reports from Welt am Sonntag and Reuters allege that President Donald Trump, who met with CureVac’s then-CEO Daniel Menichella earlier this month (who abruptly left the German biotech), had tried to lure the company over to the U.S. to continue working on its COVID-19 mRNA vaccine but, according to reports, for U.S. use only.

Menichella was replaced by former CEO Ingmar Hoerr, who had left as its leader more than two years ago, putting Menichella in charge. But he’s now, after just a week, no longer CEO.

Sponsored by BHE

[Webinar] State of Data Analytics and Machine Learning in the Life Sciences Industry: 2020 Benchmarking Survey

Thursday, June 25, 2020 | 2:00pm ET | 11:00am PT

Join us Thursday, June 25th for a look at the current state of analytics in the life sciences industry. We will present the results from our industry survey with FiercePharma on how 100 of your peers are leveraging data analytics to respond to today’s challenges and generate timely, high value insights.

CureVac said in a very brief update last night: “CureVac AG announced today that Ingmar Hoerr, CEO of the company, will take a temporary leave of absence for medical reasons. Ingmar Hoerr’s leave is not caused by coronavirus.”

For now, deputy CEO Franz-Werner Haas takes on Hoerr’s role “until his return,” though there is no word on when that will be.

Suggested Articles

Singapore is planning to outfit each of its 5.7 million residents with a simple wearable device to track people who have been exposed to COVID-19.

The agency delivered its first batch of antibody test results in May, covering a dozen products independently evaluated by the NIH and CDC.

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.